AzTrials
AzTrials

LeukemiaPhase 2NCT00446173

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

A Phase 2 study testing Busulfan, Cyclophosphamide and G-CSF in people with Leukemia, run by M.D. Anderson Cancer Center at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Primary Objective: 1. To study ex-vivo purging of autologous hematopoietic stem cells that will be used to support high-dose chemotherapy in patients with chronic myelogenous leukemia (CML). Major endpoints are neutrophil engraftment and survival. Secondary Objectives: 1. Read more about this study

Who is it for?
Ages 21 to 65 years
Conditions the study is for
Leukemia
What is being tested?
Busulfan, Cyclophosphamide and G-CSF
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
Mar 2007to Jan 2009
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with Philadelphia (Ph) chromosome positive CML < age 65 and older than 21 years.
  • Ph positive CML that is either in: 1. late 1st chronic phase (> 2 years from diagnosis) 2. early chronic phase who did not achieve complete cytogenetic remission after one year on imatinib 3. beyond first chronic phase 4. accelerated phase 5. blastic phase that has responded to therapy (characterized by the presence of < 10% bone marrow and/or circulating blasts at consent signing) 6. chronic phase, developing imatinib resistance (loss of molecular remission defined as at least a 1 log increase in the BCR-ABL/ABL ratio, in 2 time points at least 1 month apart, or loss of cytogenetic remission)
  • Patients must have a Zubrod PS < 3. Creatinine < 1.8 mg/dl
  • Serum bilirubin </= 1.5 mg/dl
  • Serum glutamate pyruvate transaminase (SGPT) < 3 x normal values
  • Patients with an HLA identical sibling are eligible if they refuse allogeneic transplantation, or if they are ineligible for allogeneic transplantation due to age.
  • DLCO >/= 50% of predicted
  • Cardiac Ejection fraction >/= 40%

Who cannot join

  • Uncontrolled life-threatening infections or comorbid condition that could impair tolerance to the regimen.
  • HIV positivity.
  • Pregnant or lactating women.
  • CML in blastic phase that has not responded to therapy given prior to enrollment in this study (characterized by the presence of more than 9% bone marrow and/or peripheral blood blasts at the time of consent signing)
  • Hepatitis B or C virus infection. Hepatitis B infection defined by positive DNA test, positive E and / or surface antigen.
  • CML in first molecular remission.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Autologous Purged Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)

Primary Objective:

  1. To study ex-vivo purging of autologous hematopoietic stem cells that will be used to support high-dose chemotherapy in patients with chronic myelogenous leukemia (CML). Major endpoints are neutrophil engraftment and survival.

Secondary Objectives:

  1. To evaluate the toxicity of ex-vivo purged autologous cells when used to support high-dose chemotherapy.
  2. To evaluate the rate and duration of cytogenetic remissions achieved with this strategy.
  3. To determine the time to platelet recovery to 20,000/mm3.
  4. To determine the one-year survival rate.
Read the detailed description

Before treatment starts, you will have a complete physical exam. You will have about 4 tablespoons of blood drawn for tests to check on the status of the disease, to check organ functions, and to check for infectious diseases (hepatitis, HIV, etc.). You will have a sample of bone marrow collected. To collect a bone marrow sample, an area of the hip or chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn through a large needle. You will also have heart (cardiac ejection fraction) and lung function tests. All of these tests are being done to make sure you are eligible for this treatment.

In order to access the blood in the circulation, a silicone catheter (small plastic tube) will be placed in the collar bone area. You will be under local anesthesia during this procedure. If you are found to be eligible to take part in this study, this catheter will be used for the collection of stem cells, infusion of chemotherapy, fluids, electrolytes, other medications, and also for blood sampling for lab tests. It will remain in your body for the length of the treatment (between 2-5 months).

Normally, there are very few stem cells in the blood. The majority of them are in the bone marrow. To help move or "mobilize" the cells needed from your bone marrow to your blood, you will be given chemotherapy followed by injections under the skin once a day of a drug called G-CSF and another drug called GM-CSF. These injections will be given over 7-21 days. The injections may be given by a nurse in the hospital, in the outpatient setting, or you may learn how to give them to yourself.

The chemotherapy you will receive to help mobilize the stem cells is cyclophosphamide. It will be given by vein over a few hours in one day. This is the first step toward collecting the stem cells necessary for transplantation later on. It is separate from the high-dose chemotherapy that you get after the transplant.

Blood samples (about 4 teaspoons each) will be drawn once a day after the cyclophosphamide to check for the numbers of stem cells in your blood and to monitor for possible side effects. If the number of stem cells in the blood is high enough, you will go to the UTMDACC Apheresis Unit and have your peripheral blood progenitor cells (PBPC, or stem cells) collected.

The procedure to collect your cells is called leukapheresis. It is similar to donating platelets to a blood bank. The cells will be removed from the blood through the catheter and the remaining blood will be given back to you through the catheter. This procedure is performed in a machine that processes the blood and separates the cells needed for transplantation, giving the rest back to you. Each leukapheresis procedure takes about 4-6 hours. You will have one leukapheresis procedure a day, for 1 to 5 days in a row, until enough stem cells are collected for the transplant and for ""back-up" in case of problems with the treated cells. If after 5 procedures, the number of cells collected is too low, additional collections of cells may be needed.

Some people may not be able to have enough cells collected through the blood. If this is the case, you may need to have bone marrow stem cells collected. You will be taken to the operating room and have multiple collections of bone marrow performed. The procedure will be performed while you are under general anesthesia. About 1 - 1.5 liters of bone marrow will be collected. You will be asked to donate your own blood before the procedure if possible. That blood will be given back to you in the operating room. Somebody else's blood may be given to you instead if you cannot donate.

After enough stem cells are collected, the cells will be treated in the laboratory, using Gleevec (imatinib mesylate) followed by ex vivo culture/purging. Culture-purging is a method that takes advantage of the fact that CML cells die when kept in laboratory culture in a shorter time period than normal blood cells. If the cells are kept alive long enough, surviving cells will be less contaminated by CML cells. Imatinib mesylate will provide a chemical way of killing the CML cells, since they are more toxic to CML cells than they are to normal cells. The culture-purging will also use three medications called "growth factors". The medications being used are stem cell factor, G-CSF, and thrombopoietin.

Busulfan and cyclophosphamide are chemotherapy drugs that are designed to kill leukemia cells. However, the combination will kill a significant amount of your bone marrow cells, which will basically stop the production of blood components. In order to restart the production, the cells that were removed and treated in the lab will be given back to you (autologous transplant).

You will be admitted to the hospital to receive high dose chemotherapy. You will be given busulfan by continuous injection (using the catheter) for 4 days, then you will be given cyclophosphamide by a continuous injection (using the catheter) for 2 days. You may also receive antibiotics, fluids, and other medications if your doctor feels it is necessary.

After you receive the chemotherapy, you will be given your treated bone marrow or blood stem cells back. To help speed up the recovery of white blood cells, you will also be given G-CSF by injection under the skin once a day until the white blood count has recovered (usually 2 to 3 weeks) and GM-CSF under the skin for a month. You may also receive antibiotics, fluids, and other medications if your doctor feels it is necessary. Blood tests (about 4 teaspoons) are repeated several times per week until blood counts are fully recovered and any side effects of the high dose therapy have resolved.

You will have check-up visits 1, 3, 6, and 12 months after the transplant. At these visits, you will have bone marrow samples collected to monitor the disease response. Bone marrow samples may also be collected for research at the same time points. These samples will be used to determine the survival of stem cells in laboratory conditions after the transplant. You will have blood collected (1- 4 tablespoons) for routine blood tests.

This is an investigational study. Busulfan, cyclophosphamide, G-CSF and GM-CSF are commercially available drugs. Up to 48 patients will take part in this study. All will be treated at M. D. Anderson.

Conditions
Leukemia
Being tested
Busulfan, Cyclophosphamide, G-CSF, GM-CSF
Keywords
Chronic Myelogenous Leukemia, Leukemia, Philadelphia (Ph) chromosome positive CML, Busulfan, Busulfex, Myleran, Cyclophosphamide, Cytoxan, Neosar, G-CSF, Filgrastim, Neupogen, GM-CSF, Sargramostim, Leukine
Medical subject headings
Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BusulfanDrug

    Also called Bulsulfex, Myleran

    130 mg/m^2 IV Daily Over 3 Hours x 4 Days

  • CyclophosphamideDrug

    Also called Cytoxan, Neosar

    60 mg/kg IV Daily Over 4 Hours x 2 Days

  • G-CSFDrug

    Also called Filgrastin, Neupogen

    10 mcg/kg Subcutaneously Once Daily

  • GM-CSFDrug

    Also called Sargramostim, Leukine

    250 mcg/kg Subcutaneously Once Daily

Study groups in NCT00446173
Study groupRoleWhat they receive
Busulfan + Cyclophosphamide + G-CSF + GM-CSFExperimentalNot described
Receives: Drug: Busulfan; Drug: Cyclophosphamide; Drug: G-CSF; Drug: GM-CSF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to absolute neutrophil count (ANC) recovery to 500

    Measured: 30 Days

  2. Survival Time

    Measured: 30 Days (Success Rate + ANC Recovery to 500)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2007 (estimated)
  2. Study startMar 2007
  3. Primary completionJan 2009
  4. Study completionJan 2009

Why it stopped: Terminated due to low accrual.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00446173
Sponsor's protocol ID
2003-0710
Status last verified
Aug 2015
First submitted
9 Mar 2007
Last updated
25 Aug 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Busulfan, Cyclophosphamide and G-CSF in people with Leukemia, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 25 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to absolute neutrophil count (ANC) recovery to 500 (time frame: 30 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in